CYD-6-86

CYD-6-86 is a novel, potent semi-synthetic diterpenoid derivative of oridonin, a natural product isolated from the herb *Isodon rubescens* (formerly *Rabdosia rubescens*). Developed by researchers at the University of Texas Medical Branch and MD Anderson Cancer Center, CYD-6-86 is designed to overcome the low aqueous solubility and poor bioavailability associated with natural oridonin. In preclinical studies, CYD-6-86 demonstrated significant anti-proliferative and pro-apoptotic activity against human breast cancer cell lines, including MDA-MB-231 and MCF-7, as well as adriamycin-resistant MCF-7 clones. Its mechanism of action involves the induction of S-phase cell cycle arrest in MDA-MB-231 cells and G0/G1-phase arrest in MCF-7 cells, accompanied by the inhibition of NF-κB and Bcl-2 expression, and the upregulation of Bax and cleaved PARP.

Other names

(3S,3aR,3a1R,6aR,7S,7aS,11aR,11bS)-7-hydroxy-5,5,8,8-tetramethyl-15-methylene-3,3a,7,7a,8,11b-hexahydro-1H-6a,11a-(epoxymethano)-3,3a1-ethanophenanthro[1,10-de][1,3]dioxine-9,14(2H)-dione1477507-22-4